Inflammatory Cardiomyopathy
11
7
7
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
9.1%
1 terminated out of 11 trials
50.0%
-36.5% vs benchmark
18%
2 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (11)
Mayo AVC Registry and Biobank
CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine
Cardiac MRI in Myocarditis and Inflammatory Cardiomyopathy
Immunosuppressive Treatment in Chronic Virus-Negative Inflammatory Cardiomyopathy
Creation of a National Multicenter Platform for the Study of Inflammatory Myocardial Disease: Pre-MYO Cohort
The Effects of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy
Role of Endomyocardial Biopsy and Aetiology-based Treatment in Patients With Inflammatory Heart Disease in Arrhythmic and Non-arrhythmic Clinical Presentations: an Integrated Approach for the Optimal Diagnostic and Therapeutic Management
Role of Endomyocardial Biopsy and Aetiology-based Treatment in Pediatric Patients with Inflammatory Heart Disease in Arrhythmic and Non-arrhythmic Clinical Presentations: an Integrated Approach for the Optimal Diagnostic and Therapeutic Management (MYOPED)
PET MRI Study in Patients With Cardiac Sarcoidosis
DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies
CZECH-ICIT (CZECH Inflammatory Cardiomyopathy Immunosuppression Trial)